Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting

We aimed to evaluate the therapeutic potential of the pan-FGFR inhibitor erdafitinib to treat dedifferentiated liposarcoma (DDLPS). FGFR expression and their prognostic value were assessed in a series of 694 samples of well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). The effect of erd...

Full description

Bibliographic Details
Main Authors: Bérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, Emmanuel Chamorey, Ilaria Di Mauro, Vanessa Chaire, Pascal Finetti, Renaud Schiappa, François Le Loarer, Isabelle Birtwisle-Peyrottes, Jean-François Michiels, François Bertucci, Florence Pedeutour, Antoine Italiano, Laurence Bianchini
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
liposarcoma
FGFR
MDM2
JNJ42756493
RG7388
Online Access:https://www.mdpi.com/2072-6694/12/10/3058

Internet

https://www.mdpi.com/2072-6694/12/10/3058

Similar Items